China SXT Pharmaceuticals, Inc. (SXTC) 是一家上市公司 属于 医疗保健 板块,经营于 制药 - 专科与仿制药 行业. 公司总部位于 Taizhou, 中国. 现任CEO为 Feng Zhou.
SXTC 拥有 IPO日期为 2019-01-04, 75 名全职员工, 在 NASDAQ Capital Marke, 市值为 $1.59M.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.